Eur J Heart Fail:心脏移植者晚期移植物衰竭的发生率、危险因素及临床结局!

2018-03-01 xing.T MedSci原创

由此可见,心脏移植后晚期移植物衰竭较为常见,因为它与不良结局有关。排斥反应和移植心脏血管病是最常见的原因。

近日,心血管领域权威杂志European Journal of Heart Failure上发表了一篇研究文章,研究人员旨在对心脏移植术后晚期移植物衰竭的发生率、危险因素及临床结局进行分析。

研究人员进行了一项观察性的单中心研究,研究对象是1991至2014年间接受心脏移植手术的547名术后存活的患者。晚期移植物衰竭被定义为出院后由于这种疾病首次住院。

在平均8.4 ± 6年的随访期间,178例(32.5%)患者接受住院治疗,由于晚期移植物衰竭[发生率为3.6例每100病人每年,95%可信区间(CI)为3.1-4.2]。移植前糖尿病、移植前高跨肺压梯度和较低的供者/受者重量比与移植物衰竭风险增加独立相关。移植心脏血管病变、细胞排斥反应等级≥1R和抗体介导排斥等级≥1级的患者比例分别为50.6%、44.9%和19.2%。其中60.1%的患者左室射血分数≥50%。诊断移植物衰竭后1年、5年、10年和15年的未再移植存活率分别为72.2%、38.4%、18.4%和7.5%,因失代偿性心衰再住院的发生率为每100名病人每年有40.9次(95%CI为36.6-46.1)。需要正性肌力药物治疗、存在移植心脏血管病变、较高的血清肌酐水平、较低的射血分数和较低的血清钠水平是预后较差的独立预测因素。

由此可见,心脏移植后晚期移植物衰竭较为常见,因为它与不良结局有关。排斥反应和移植心脏血管病是最常见的原因。

原始出处:


Ángela López-Sainz, et al. Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes.European journal of heart failure. 2018. http://onlinelibrary.wiley.com/doi/10.1002/ejhf.886/full

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-12-05 xuyong535
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-02 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-02 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1745279, encodeId=82d91e45279cc, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 05 14:19:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843149, encodeId=3247184314962, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sun Mar 18 14:19:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826427, encodeId=896c182642e45, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 10 00:19:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356713, encodeId=525a1356e136f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562858, encodeId=ff24156285866, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620712, encodeId=53011620e1284, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Fri Mar 02 15:19:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291888, encodeId=751929188836, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Thu Mar 01 06:35:52 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-01 wzb521zf

    一起学习学习

    0

相关资讯

Sci Rep:代谢组学研究确定了大鼠心脏移植急性排斥反应相关生物标志物

这项研究结果表明D-塔格糖、胆碱、C16二氢鞘氨醇和D-谷氨酰胺对心脏移植后的急性排斥反应的早期诊断具有高度的敏感性和特异性。

Circulation:CD16依赖性自然杀伤细胞活化的遗传学和功能性分析可以识别心脏同种异体移植物脉管病的高风险患者

这项研究揭示了CD16依赖性NK细胞活化通路在促进移植动脉硬化中的重要作用。

JAHA:等待移植时的抑郁症与社会隔绝在心脏移植8年后生存率中的作用

等待移植时的低度抑郁和社会整合,与HTx 后的生存机会增加有关。

JACC:心脏移植后恶性肿瘤的发生风险明显增高!

恶性肿瘤的发生是接受心脏移植治疗患者的重要并发症之一。本研究的目的旨在评估心脏移植患者恶性肿瘤的发生率、类型以及预测因素。本研究纳入了17587名仅接受了心脏移植的成年人,主要终点事件是新发恶性肿瘤的发生、类型以及出现时间。结果发现,接受心脏移植后的1-5年,新发恶性实体肿瘤的发生率为10.7%,主要类型有:皮肤癌(7%)、非皮肤实体癌(4%)和淋巴组织增生性疾病(0.9%)。各类型肿瘤的发生时间

JAHA:系统性右心室和心脏移植后先天性心脏病的低鼻NO

CHD患者低nNO的患病率高,系统性右心室和心脏移植的几率最高。

JACC:西罗莫司缓解心脏移植后免疫反应更佳

既往有报道称西罗莫司(SRL)在缓解心脏移植后的移植物血管病(CAV)方面的效果要优于钙调神经磷酸酶抑制剂(CNI),然而缺乏远期的疗效报道。本研究旨在评估用SRL代替CNI作为维持治疗心脏移植后的CAV远期的有效性和安全性。本研究纳入了402例心脏移植后的患者,这些患者有的仅接受CNI治疗(n = 134),有的用SRL代替了CNI作为一级免疫抑制预防治疗(n = 268),CAV通过冠脉血管内